Miruvor
Sign up
The short answer

What studies of d-ribose found

4papers on d-ribose
36people in 1 study testing d-ribose alone
0randomised trials, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: D-ribose might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 4 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. D-ribose · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Cognition (brain fog)1 study · 36 people took d-ribose Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).

Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of D-ribose on cognition (brain fog) in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 1 study
  1. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)

    People in the study
    41 in the study · 36 with outcome data
    Dose
    5 g t.i.d, three times per day (t.i.d.)
    Outcome
    Mental clarity discrete Visual Analog Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 36 people took d-ribose Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).

Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)

Fatigue improved.

The evidence is very uncertain about the effect of D-ribose on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 1 study
  1. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)

    People in the study
    41 in the study · 36 with outcome data
    Dose
    5 g t.i.d, three times per day (t.i.d.)
    Outcome
    Energy level discrete Visual Analog Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 36 people took d-ribose Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).

Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)

Pain improved.

The evidence is very uncertain about the effect of D-ribose on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 1 study
  1. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)

    People in the study
    41 in the study · 36 with outcome data
    Dose
    5 g t.i.d, three times per day (t.i.d.)
    Outcome
    Pain discrete Visual Analog Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 36 people took d-ribose Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).

Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)

Sleep improved.

The evidence is very uncertain about the effect of D-ribose on sleep in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 1 study
  1. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)

    People in the study
    41 in the study · 36 with outcome data
    Dose
    5 g t.i.d, three times per day (t.i.d.)
    Outcome
    Sleep discrete Visual Analog Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 36 people took d-ribose Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).

Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)

Overall symptoms improved.

The evidence is very uncertain about the effect of D-ribose on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 1 study
  1. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)

    People in the study
    41 in the study · 36 with outcome data
    Dose
    5 g t.i.d, three times per day (t.i.d.)
    Outcome
    Well-being discrete Visual Analog Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported3 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Anxiety or irritability1 study
Dizziness1 study
Nausea or stomach upset1 study

All papers

  1. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.2006 · no comparison group · 41 in the study · 36 with outcome data
    Summary

    This open-label uncontrolled pilot study enrolled 41 adult patients diagnosed by their physicians as having FMS and/or CFS, recruited through an FMS and CFS e-mail newsletter and website. Patients were instructed to take one scoop (5-g) of D-ribose three times per day (t.i.d.) mixed with food, water, or another beverage until the 280-g container was empty; the average length of time on D-ribose was 25 days (range, 17 to 35 days). Five of 41 enrolled patients were considered noncompliant and excluded, leaving 36 in the final analysis. Patients completed discrete visual analog scales for energy, sleep, mental clarity, pain, and well-being before and at completion, plus a global subjective rating. In the 36 analysed patients, mean scores improved from 3.8 to 5.5 for energy, 4.8 to 6.0 for sleep, 4.9 to 5.7 for mental clarity, 4.9 to 5.6 for pain, and 4.3 to 5.6 for well-being. Twenty-three of 35 patients (65.7%) completing the assessment reported improvement (somewhat better to much better). Of five noncompliant patients, three stopped taking D-ribose because of a hyperanxious feeling (one patient), lightheadedness (one patient), and increased appetite (one patient); among 36 completers, one patient experienced transient nausea and another felt mild anxiety, both reversed by lowering the dose. The authors state limitations including lack of a placebo group, no clinic visits, subjective outcomes only, and continuation of other stable treatments.

  2. HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
    Summary

    This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.

  3. Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
    Summary

    Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.

  4. Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review.2017 · systematic review
    Summary

    This systematic review asked whether dietary modification alleviates chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) symptoms. It searched Scopus, CINAHL Plus, Web of Science and PsycINFO from 1994 to 2014 in May 2014, with an update from June 2014 to August 2016, and included 22 studies across animal and human designs. Treatments included D-ribose, probiotic, oral vitamin D3, vitamin and mineral supplements, polynutrient supplementation, magnesium, calcium, ginseng, EFA supplements, glutamine, a low-sugar low-yeast diet, and polyphenols (AMF, EGCG, naringin). D-ribose showed significant improvement in energy levels in compliant analysis (p<0.0001, 95%CI 1.1–2.2), and 65.7% reported improved overall subjective feelings. Probiotic: six of 15 reported subjective improvement and neurocognitive measures improved (p=0.04), but no significant overall change. Vitamin D3 showed no statistically significant improvement in fatigue or inflammatory/oxidative markers. One vitamin/mineral supplement showed improvements in fatigue (p=0.0009) and some quality-of-life measures; another found no significant relationship. Polynutrient supplementation found no significant results. Magnesium improved fatigue at six months (p=0.002) but not at two years; calcium improved fatigue (p=0.01) based on five participants; ginseng was most helpful in 56%. An EFA case study dropped depression scores from 27 to 3 at 16 weeks; an EFA versus sunflower-oil placebo trial found no significant difference. Glutamine showed no significant symptom change; placebo showed decreases in emotionality and sleep problems (p=0.02). The low-sugar low-yeast diet showed no significant difference. Animal polyphenol studies reported significant improvements (p<0.05). The review did not report side effects or withdrawals.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime